COMP <GO>
KRYS vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
Krystal Biotech Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: KRYS 6
— ABBV 7
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ABBV
LAST: $324.55 (+0.97%) • MKT CAP: $9.61B
roic
16.50%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KRYS VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KRYS | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 70.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 16.50% | 29.00% | -12.50 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 53.4x | 33.3x | +20.10 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 1.97% | 3.47% | -1.50 | ABBV | /fcf-yield <GO> |
| Operating Margin | 41.50% | 24.60% | +16.90 | KRYS | /operating-margins <GO> |
| Net Profit Margin | 52.60% | 6.90% | +45.70 | KRYS | /net-margins <GO> |
| Revenue Growth (YoY) | 33.90% | 8.60% | +25.30 | KRYS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.33 | +20.67 | KRYS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | KRYS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.2 | 65.1 | -16.90 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 1.15 | -0.24 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 39.4x | 113.1x | -73.70 | KRYS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.61B | $513.86B | -$504.25B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KRYS REV | ABBV REV | KRYS GROSS % | ABBV GROSS % | KRYS FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $389.1M | $61.16B | — | 70.2% | $188.9M | $17.82B |
| FY 2024 | $290.5M | $56.33B | — | 70.0% | $119.2M | $17.83B |
| FY 2023 | $50.7M | $54.32B | — | — | -$91.1M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KRYS // BETA 0.91
ABBV // BETA 1.15